(Q43597458)

25 November 2017

The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension (English)

1 reference

25 November 2017

1 reference

1 reference

Stewart WC

1

1 reference

25 November 2017

Day DG

2

1 reference

25 November 2017

Stewart JA

3

1 reference

25 November 2017

Schuhr J

4

1 reference

25 November 2017

Latham KE

5

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

American Journal of Ophthalmology

25 November 2017

1 reference

25 November 2017

131

1 reference

25 November 2017

5

1 reference

25 November 2017

631-635

1 reference

The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Latanoprost 0.005% and anterior segment uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Effects of brimonidine on aqueous humor dynamics in human eyes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Brimonidine tartrate: a one-month dose response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2800%2900902-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9394(00)00902-8

1 reference

25 November 2017

1 reference